Gold is 2025’s best performer. UBS sees more upside
SAN DIEGO—Prante Gerhard, a director at Cibus, Inc. (NASDAQ:CBUS), a small-cap biotechnology company with a market capitalization of $85.45 million, sold 1,150 shares of Class A Common Stock on February 5, 2025. The shares were sold at $2.52 each, amounting to a total transaction value of $2,898. The transaction comes amid a challenging period for CBUS, with the stock down 85% over the past year. Following this sale, Gerhard holds 23,807 shares of the company. This transaction was conducted automatically under a Rule 10b5-1 trading plan that Gerhard adopted on August 16, 2024. With the company’s next earnings report scheduled for February 28, investors seeking deeper insights can access comprehensive analysis through InvestingPro, which offers exclusive financial health metrics and 14 additional investment tips for CBUS.
In other recent news, Cibus, a pioneer in agricultural gene editing, reported a net loss of $201.5 million in its Third Quarter 2024 Earnings Conference Call, despite significant strides in the development of the Trait Machine process and notable partnerships with major seed companies. In a parallel development, the company has announced plans to raise approximately $22.6 million through a direct offering of about 9 million shares of its common stock, as disclosed by Canaccord Genuity analysts. This capital is intended to fund the advancement of Cibus’s gene-edited plant productivity traits and the further development of its soybean platform.
Furthermore, Cibus has approved a new base salary of $320,000 for executive Carlo Broos, as indicated in a recent filing with the Securities and Exchange Commission. This decision comes without any additional context regarding the company’s financial performance or strategic direction.
In terms of stock analysis, Canaccord Genuity has lowered the stock’s price target from $20.00 to $18.00, while still recommending a Buy rating. In a similar move, Jefferies has also adjusted its price target for Cibus, reducing it to $5.00 from the previous $8.00, but maintained its Hold rating on the stock.
In the near future, the company plans to launch herbicide-resistant and Pod Shatter Reduction traits, targeting significant market opportunities in the U.S., Latin America, and Asia. These recent developments reflect Cibus’s ongoing commitment to advancing its gene editing technology within the agricultural sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.